Price regulation and relative delays in generic drug adoption
-
Frequently Asked Questions: Drug Master File Fee
Pharma Live, , Regulatory Affairs, 0
Q1. What DMFs incur fees? Only DMFs that cover the manufacture of an API (Type II API DMFs) for...
-
Leveraging Third-Party Audits in Pharma/Biotech Industries – Courtesy (Pharmaceutical Manufacturing)
Pharma Live, , Regulatory Affairs, 0
Those of us in the competitive and highly regulated pharmaceutical, biotechnology and medical device industries understand the need to...
-
Telmisartan: no double-dipping says CJEU, as it avoids answering all the questions – Courtesy (The SPC Blog)
Pharma Live, , Regulatory Affairs, 0
The Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK...
-
-
Formulation factors affecting acceptability of oral medicines in children – ScienceDirect
Pharma Live, , Regulatory Affairs, 0
Acceptability of medicines in children and caregivers affects safety and effectiveness of medicinal treatments. The pharmaceutical industry is required...
-
Reference pricing, competition, and pharmaceutical expenditures: Theory and evidence from a natural experiment
Pharma Live, , Regulatory Affairs, 0
1-s2-0-s0047272710001751-main-1Download
-
Regulatory Affairs: “Studty Report of New Drug Registration Process in European Union”
Pharma Live, , Regulatory Affairs, 0
About Authors:Yogeshkumar B. Viradiya*, Manoj B. Dagwar, Swapnil T. LanjewarInstitute of Management Sciences and Research (IMSR),Nagpur, [email protected] Abstract:European Union...
-
Price regulation in the pharmaceutical industry: Prescription or placebo?
Pharma Live, , Regulatory Affairs, 0
1-s2-0-0167629695000224-mainDownload
![](https://ml7mn4k5dnn0.i.optimole.com/w:289/h:289/q:eco/f:best/https://interactivepharm.com/wp-content/uploads/2022/08/Show-your.jpg)